Bristol-Myers Squibb Company (BMY) stock analysis
BMY · Bristol-Myers Squibb Company
Latest recorded price: USD 62.94
Model-estimated fair value: USD 130.28. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Drug Manufacturers - General
At $62.94, BMY trades 51.7% below the model's base-case value of $130.28. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $101.39 in the conservative case and $162.44 in the optimistic case, with a valuation confidence score of 55/100. About 81% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 1.4%, free cash flow margin 26.7%, ROIC 15.2%. The model flags 3 risk signals for this company (1 high severity).